The Immunogenicity Database Collaborative (IDC): A Standardized, Publicly Available Database for Clinical Immunogenicity Observations and Insights
The Immunogenicity Database Collaborative (IDC), ; Agnihotri, S.; Gonzalez-Nolasco, B.; Monian, B.; Pattijn, S.; Ackaert, C.; Wu, P.; Kettenberger, H.; Tourdot, S.; Hickling, T.; Hu, Z.; Higgs, R. E.; Leventhal, D. S.
Show abstract
The incidence and impact of anti-drug antibodies (ADAs) against biotherapeutics remain difficult to predict, limiting efforts to mitigate immunogenicity risk prior to clinical trials. Existing data are fragmented across disparate sources with inconsistent definitions, representing a key barrier to progress in the field. Here, we present the Immunogenicity Database Collaborative (IDC) and its release of the Immunogenicity Database (DB) V1: a structured clinical immunogenicity dataset integrating therapeutic characteristics, sequence, and patient cohort-level data from publicly available sources. The dataset includes 4,146 ADA datapoints, 1,788 cohorts, 727 clinical trials and 218 therapeutics. We highlight trends in ADA incidence, evaluate sources of variability, and identify driving factors of immunogenicity risk. This work provides a foundational resource to standardize and support immunogenicity risk assessment across the industry. It also provides an initial data architecture and invites the research community to contribute towards future expansions of the database into key areas of interest to the field.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Standardized Metric to Enhance Clinical Trial Design and Outcome Interpretation in Type 1 Diabetes 95%
- Monoclonal antibody levels and protection from COVID-19 94%
- NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes 93%
Similar papers in this journal
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes 90%
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model 87%
- Savor the flavor — a randomized double-blind study on taste-enhanced placebo analgesia in healthy volunteers 87%
Similar papers in this journal
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 90%
- Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics 89%
- Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease 89%
Similar papers in this journal
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 94%
- Antibody therapy reverses biological signatures of COVID-19 progression 94%
- Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics 93%
Similar papers in this journal
- Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration 92%
- Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study 92%
- Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.